Khiron Secures Medical Cannabis Endorsements from Two of the Largest Medical Associations in Colombia
The Colombian Association of Internal Medicine and the Colombian Association of Neurology agree to support Khiron’s development of medical cannabis education, research and professional programs for nearly 3,000 doctors in Colombia
TORONTO, June 11, 2018 /CNW/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), a Canadian integrated medical cannabis company with its core operations in Colombia, announced today that it has received endorsements and signed co-operation agreements with two of the largest and most recognized medical associations in the country: The Colombian Association of Internal Medicine (ACMI) and the Colombian Association of Neurology (ACN). As a result, Khiron becomes the first medical cannabis company in Colombia to be endorsed by two medical associations and to be in a position to directly introduce its brand to a national audience of almost 3,000 doctors.
The co-operation agreements with the associations will allow Khiron to provide doctors with direct access to a rich repository of information, support and learning resources about extract-based medical cannabis products. In addition, these resources will enable doctors to receive professional training support on prescribing medical cannabis to their patients through Khiron’s e-learning platform and academic events in the main cities of Colombia during 2018.
“We are proud to receive the endorsements of these prestigious medical associations and look forward to working closely with their members to support their professional development goals around the use of medical cannabis as a treatment option for patients,”
said Alvaro Torres, CEO of Khiron Life Sciences.
“It is also a significant opportunity to position Khiron as a leading brand in the minds of doctors and to drive patient adoption rates in Colombia.”
The agreement with ACMI will lead towards Colombia becoming an important contributor to the body of global research on medical cannabis. Khiron will collaborate with ACMI in developing learning modules to offer health professionals a greater understanding of medical cannabis and the related treatment options for an estimated 5.6 million patients in Colombia.
The endorsement from ACN, which has more than 400 members in Colombia, also opens a gateway for the investigation of alternative courses of treatment with medical cannabis derivatives and will bring academic and scientific support for medical cannabis to member physicians across the country.
About the Colombian Association of Internal Medicine (ACMI)
The Colombian Association of Internal Medicine (ACMI), has nearly 60 years of existence and is today one of the largest and most prestigious medical organizations in Colombia. It is the country’s leading professional organization for internal medicine specialists, with approximately 2,450 members across the country.
About the Colombian Association of Neurology (ACN)
The Colombian Association of Neurology (ACN) is a private, scientific, autonomous, apolitical, non-profit organization, which brings together specialists in clinical and pediatric neurology, non-neurologists and other professionals interested in the study, prevention and the treatment of diseases of the central and peripheral nervous system, as well as in the improvement of teaching and of research in neurosciences.
About Khiron Life Sciences Corp.
Khiron Life Sciences is a Canadian integrated medical cannabis company with its core operations in Colombia. Khiron combines leading international scientific expertise, agricultural advantages and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America. Khiron has received licences in Colombia for high- and low-tetrahydrocannabinol (THC) medical cannabis, and has received all licences required for the cultivation, production, domestic distribution, and international export of both THC and cannabidiol (CBD) medical cannabis.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Filing Statement which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
For further information: The Company can be accessed at: www.khiron.ca, Darren Collins, Chief Financial Officer, Direct: +1 (705) 527 3564, Email: email@example.com; Canada Investor Relations: Nicole Marchand, GRIT Capital, T: +1 (416) 428-3533, E: firstname.lastname@example.org; U.S. Investor Relations, Lisa Wilson, In-Site Communications, Inc., T: +1 (917) 543-9932, E:email@example.com
Released June 11, 2018